CONFERENCE:
FEBRUARY 28 – MARCH 1

PRE-CONFERENCE COURSES:
FEBRUARY 27 – 28

REGISTER AT: Lipid.org/SpringCLU

#NLASpringCLU
Complex Lipid Management Self-Assessment Program (CLM-SAP): 2018 Guideline on the Management of Blood Cholesterol

The Complex Lipid Assessment Self-Assessment Program (CLM-SAP) offers you actionable insight into the 2018 ACC/AHA Multi-Society Guideline on the Management of Blood Cholesterol. The CLM-SAP is designed to reduce knowledge gaps in the implementation of evidence-based therapies to reduce the risk of ASCVD. This online CME/CE activity is FREE of CHARGE to both members and non-members.

To learn more, visit lipid.org/education/clmsap/19

National Lipid Association Self-Assessment Program (NLA-SAP), Edition V

The latest edition of the NLA Self-Assessment program is being released in mid-November. Stay ahead of the curve with this essential self-study tool for assessing and improving your clinical problem-solving skills in the diagnosis and management of dyslipidemia patients. The new SAP offers four online modules in a helpful Q&A format with suggested references for further reading.

To learn more, visit lipid.org/education/nlasap

Lipid Specialist Certification

Once you’ve mastered the latest evidence-based treatment guidelines in delivering patient care, earning certification as a Lipid Specialist is your pathway to professional excellence, enhanced credibility and expanded career opportunities.

To learn more, visit lipid.org/lipidspecialist

Join and SAVE! If you’re not an NLA member, you can join and register at the same time for even bigger savings! Click on the Join and Save Non-Member Registration Button, complete your membership application order and payment, and you will be simultaneously registered for the meeting at the discounted rate.

*The trainee rate is available for those individuals actively enrolled in a graduate or postgraduate training program for the treatment or investigation of lipid disorders and in pursuit of full credentialing in their specialized area of medical study. A letter from the program director or the school registrar must accompany the application.

**PRE-CONFERENCE COURSES**

*Foundations of Lipidology*

**THURSDAY, FEBRUARY 27 AND FRIDAY, FEBRUARY 28**

- **NLA Member Rate**: $545 (after 02/05/2020)
- **Non-Member Rate**: $895
- **Trainee Rate**: $75

Attend Foundations of Lipidology, perfect for first-time attendees of the CLU.

- In-depth indoctrination to lipid science
- Development of core competencies in diagnoses and treatment of dyslipidemia
- Interactive course design

For more information, go to page 12 or visit lipid.org/foundations.

*Masters in Lipidology*

**THURSDAY, FEBRUARY 27 AND FRIDAY, FEBRUARY 28**

- **NLA Member Rate**: $750
- **Non-Member Rate**: $1,250
- **Trainee Rate**: $395

Register for the Masters in Lipidology course today. The new case-based, interactive agenda will improve your clinical decision-making skills and help prepare you for certification in clinical lipidology.

- Intensive two-day training course
- In-depth review of the core curriculum in clinical lipidology
- Ideal for the advanced-level practitioner

For more information, go to page 13 or visit lipid.org/masters.
Want to learn about the latest and greatest in lipid-lowering medications? Come to the kickoff session for the National Lipid Association’s Spring Clinical Lipid Update in Denver, Colorado, “Drugs in the Pipeline.” Included in this session will be information about bempedoic acid and inclisiran, both of which are efficacious in lowering LDL-C, and evinacumab, a fully human monoclonal antibody that has been shown to lower LDL-C in patients with homozygous FH. Most exciting of all is that these three novel medicines have unique mechanisms of action. Our experts will also review pemafibrate, a fibric acid derivative that currently being studied in a large cardiovascular outcome trial. You will walk away from this session with knowledge on how these drugs work and potential efficacy in your patients with dyslipidemia. This is a must-see session for all lipid specialists.

**FEATURED SESSIONS/PRESENTATIONS**

**SESSION I**  
**Drugs in the Pipeline**  
**Friday, February 28 • 4:00 – 6:00 PM**

MODERATOR  
Joseph J. Saseen, PharmD, CLS, FNLA

Want to learn about the latest and greatest in lipid-lowering medications? Come to the kickoff session for the National Lipid Association’s Spring Clinical Lipid Update in Denver, Colorado, “Drugs in the Pipeline.” Included in this session will be information about bempedoic acid and inclisiran, both of which are efficacious in lowering LDL-C, and evinacumab, a fully human monoclonal antibody that has been shown to lower LDL-C in patients with homozygous FH. Most exciting of all is that these three novel medicines have unique mechanisms of action. Our experts will also review pemafibrate, a fibric acid derivative that currently being studied in a large cardiovascular outcome trial. You will walk away from this session with knowledge on how these drugs work and potential efficacy in your patients with dyslipidemia. This is a must-see session for all lipid specialists.

**Complex Drug-Drug Interactions**  
**Part of Session III: One Size Does Not Fit All: Evidence-based Use of Statin Therapy in the Special Populations**  
**Saturday, February 29 • 10:05 – 10:25 AM**

Donald G. Lamprecht, Jr., PharmD, BCPS, CLS, FNLA

Statins are the cornerstone of therapy for the treatment and prevention of atherosclerotic cardiovascular disease. While generally safe and well tolerated, adverse drug reactions (ADRs), such as myopathy or rhabdomyolysis, can occur. The incidence of these ADRs is higher in the setting of increased systemic exposure to statins. Complex statin drug-drug interactions (DDIs) may result in significant increases in systemic exposure and are associated with an increased risk of statin ADRs. Medically complex patients represent a particularly high-risk group for statin DDIs. Certain medications used to treat conditions such as HIV, solid organ transplant, and atrial fibrillation have clinically important interactions with statins. In these patient populations, a careful approach to statin selection is required to prevent potentially dangerous DDIs.

Choosing the appropriate statin and dosage can be challenging, particularly when limited or conflicting guidance exists. By using a case-based approach, attendees of this presentation will learn to identify, assess the magnitude of, and interpret the clinical relevance of select statin DDIs. An emphasis will be placed on employing basic pharmacokinetic principles to optimize statin selection and prevent potentially harmful combinations in patients with complex underlying disease states.

**Physiologic and Epidemiologic Evidence for EPA**  
**Part of Session VIII: Is the Rising Tide of Support for EPA Warranted or Just Another Fish-Tale?**  
**Sunday, March 1 • 9:45 – 10:05 AM**

Kevin C. Maki, PhD, CLS, FNLA

In the late 1970s, studies showed that Greenland Inuits, who subsist largely on fatty fish and seafood, had low rates of myocardial infarction compared with those in Western countries. Observational evidence from hundreds of investigations consistently supports an inverse association between higher intakes of long-chain omega-3 fatty acids and biomarkers of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) with coronary heart disease (CHD) outcomes, while evidence is mixed regarding stroke. More than 20 randomized controlled trials (RCTs) have been completed using low-dosage EPA and DHA, yielding mixed results regarding the effects on risk for CHD and generally not supporting a protective effect for stroke. Two RCTs testing EPA alone (the Japan EPA Lipid Intervention Study [JELIS]) and the Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial [REDUCE-IT]) showed evidence for decreased risk of major adverse coronary and cardiovascular events (including stroke), respectively. At present, the strongest evidence is for use of EPA alone at higher dosages. In addition to triglyceride lowering, EPA has effects on inflammation, oxidation, membrane structure and fluidity, as well as hemodynamic, endothelial and platelet functions. Currently the relative importance of these various potentially beneficial mechanisms is uncertain and a topic of intense investigation.
## SCHEDULE-AT-A-GLANCE

### THURSDAY
February 27

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 – 7:30 AM</td>
<td>Masters in Lipidology Registration</td>
</tr>
<tr>
<td>7:30 – 8:00 AM</td>
<td>Foundations of Lipidology Registration</td>
</tr>
</tbody>
</table>

### FRIDAY
February 28

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:30 – 6:00 PM</td>
<td>CLU Registration</td>
</tr>
<tr>
<td>7:30 – 2:20 PM</td>
<td>Masters in Lipidology</td>
</tr>
<tr>
<td>8:00 – 2:30 PM</td>
<td>Foundations of Lipidology</td>
</tr>
<tr>
<td>4:00 – 6:00 PM</td>
<td>Session I</td>
</tr>
</tbody>
</table>

### SATURDAY
February 29

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 AM – 1:00 PM</td>
<td>CLU Registration</td>
</tr>
<tr>
<td>8:00 – 9:30 AM</td>
<td>Session II</td>
</tr>
<tr>
<td>10:00 – 11:45 AM</td>
<td>Session III</td>
</tr>
<tr>
<td>1:00 – 2:30 PM</td>
<td>Session IV</td>
</tr>
<tr>
<td>2:40 – 3:40 PM</td>
<td>Session V</td>
</tr>
<tr>
<td>3:50 – 5:20 PM</td>
<td>Session VI</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:45 AM – 12:00 PM</td>
<td>PLA &amp; SWLA Chapter News &amp; Notes</td>
</tr>
<tr>
<td>12:00 – 1:00 PM</td>
<td>Expert Theater Presentations</td>
</tr>
<tr>
<td>7:00 – 7:30 PM</td>
<td>Women in Lipidology Event</td>
</tr>
<tr>
<td>7:00 AM – 7:30 PM</td>
<td>Welcome Reception in Exhibit Hall</td>
</tr>
</tbody>
</table>

### SUNDAY
March 1

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 – 11:10 AM</td>
<td>CLU Registration</td>
</tr>
<tr>
<td>7:00 – 7:50 AM</td>
<td>Breakfast</td>
</tr>
<tr>
<td>8:00 – 9:30 AM</td>
<td>Session VII</td>
</tr>
<tr>
<td>9:40 – 11:05 AM</td>
<td>Session VIII</td>
</tr>
</tbody>
</table>

### SPECIAL EVENTS

#### SATURDAY
February 29

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:45 AM – 12:00 PM</td>
<td>PLA &amp; SWLA Chapter News &amp; Notes</td>
</tr>
<tr>
<td>12:00 – 1:00 PM</td>
<td>Expert Theater Presentations</td>
</tr>
<tr>
<td>7:00 – 7:30 PM</td>
<td>Women in Lipidology Event</td>
</tr>
<tr>
<td>7:00 AM – 7:30 PM</td>
<td>Welcome Reception in Exhibit Hall</td>
</tr>
</tbody>
</table>

### Mobile App

Get the latest meeting updates and educational content directly to your mobile device with the NLA meeting app!

Complimentary WiFi will be available to all meeting attendees to access the NLA meeting app. The app is compatible with laptops, tablets and smart phones.

### Get Engaged

Be part of the conversation and stay in the know by following the NLA on Twitter, Instagram, Facebook and LinkedIn. The NLA provides meeting highlights, society updates and much more on these social networks. Use hashtag #NLASpringCLU when posting about the meeting.
### Friday, February 28

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:45 – 3:55 PM</td>
<td>Chapter Presidents Welcome &amp; Introduction</td>
</tr>
<tr>
<td>4:00 – 4:05 PM</td>
<td>Pre-Session Assessment</td>
</tr>
<tr>
<td>4:05 – 4:20 PM</td>
<td>Pemafibrate                                                            Savitha Subramanian, MD</td>
</tr>
<tr>
<td>4:20 – 4:35 PM</td>
<td>Bempedoic Acid                                                         Anne C. Goldberg, MD, FNLA*</td>
</tr>
<tr>
<td>4:35 – 4:50 PM</td>
<td>Inclisiran                                                             Christie M. Ballantyne, MD, FNLA*</td>
</tr>
<tr>
<td>4:50 – 5:05 PM</td>
<td>Update on Evinacumab: ANGPTL3 and Lipid Management                    P. Barton Duell, MD, FNLA</td>
</tr>
<tr>
<td>5:05 – 5:35 PM</td>
<td>Speakers Panel with Moderator</td>
</tr>
<tr>
<td>5:35 – 6:00 PM</td>
<td>Q&amp;A Panel &amp; Post-Session Assessment</td>
</tr>
<tr>
<td>6:00 – 7:00 PM</td>
<td>Welcome Reception in Exhibit Hall</td>
</tr>
</tbody>
</table>

### Saturday, February 29

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 – 7:50 AM</td>
<td>Breakfast in Exhibit Hall</td>
</tr>
<tr>
<td>7:50 – 8:00 AM</td>
<td>Opening Remarks</td>
</tr>
<tr>
<td>8:00 – 8:05 AM</td>
<td>Pre-Session Assessment</td>
</tr>
<tr>
<td>8:05 – 8:25 AM</td>
<td>Primary Prevention: Seeking Individuality and Personalization of Preventive Therapies Margo B. Minissian, PhD, ACNP, CLS, FNLA</td>
</tr>
<tr>
<td>8:25 – 8:45 AM</td>
<td>Secondary Prevention: Not All ASCVD is Created Equal                   Kim K. Birtcher, PharmD, CLS, FNLA</td>
</tr>
<tr>
<td>8:45 – 9:05 AM</td>
<td>Beyond the Usual Suspects: What is the Current Role of Genetic Testing in ASCVD Risk Assessment? Zahid Ahmad, MD</td>
</tr>
<tr>
<td>9:05 – 9:30 AM</td>
<td>Q&amp;A Panel &amp; Post-Session Assessment</td>
</tr>
<tr>
<td>9:30 – 10:00 AM</td>
<td>Break in Exhibit Hall</td>
</tr>
<tr>
<td>10:00 – 10:05 AM</td>
<td>Pre-Session Assessment</td>
</tr>
<tr>
<td>10:05 – 10:25 AM</td>
<td>Complex Drug-Drug Interactions                                         Donald G. Lamprecht Jr., PharmD, BCPS, CLS, FNLA</td>
</tr>
<tr>
<td>10:25 – 10:45 AM</td>
<td>SHARPening Statin Therapy Recommendations in Chronic Kidney Disease Rachel Lowe, PharmD, BCPS</td>
</tr>
<tr>
<td>10:45 – 11:05 AM</td>
<td>Statin Therapy in Older Primary Prevention Patients                Eric K. Gupta, PharmD, CLS, FNLA</td>
</tr>
<tr>
<td>11:05 – 11:25 AM</td>
<td>Case Presentation and Panel Discussion</td>
</tr>
<tr>
<td>11:25 – 11:45 AM</td>
<td>Q&amp;A Panel &amp; Post-Session Assessment</td>
</tr>
<tr>
<td>11:45 AM – 12:00 PM</td>
<td>PLA &amp; SWLA Chapter News &amp; Notes</td>
</tr>
<tr>
<td>12:00 – 1:00 PM</td>
<td>Lunch in Exhibit Hall</td>
</tr>
<tr>
<td>12:00 – 1:00 PM</td>
<td>Expert Theater Presentations</td>
</tr>
</tbody>
</table>

### Session IV: Improving Outcomes for the Statin Intolerant Patient

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:00 – 1:05 PM</td>
<td>Introductions &amp; Pre-Session Assessment</td>
</tr>
<tr>
<td>1:05 – 1:10 PM</td>
<td>Statin Intolerant Patient Case Overview                               Peter H. Jones, MD, FNLA*</td>
</tr>
<tr>
<td>1:10 – 1:25 PM</td>
<td>Expert Case Management: Drugs Don’t Work When They’re Left in the Bottle Mary Katherine Cheeley, PharmD, CLS, FNLA</td>
</tr>
</tbody>
</table>
Saturday, February 29

1:25 – 1:45 PM  Expert Case Management: Alternative or Additive Therapeutic Approaches  
Kevin C. Maki, PhD, CLS, FNLA

1:45 – 2:10 PM  Expert Case Management: What's next after a Myocardial Infarction (MI)?  
Alan S. Brown, MD, FNLA*

2:10 – 2:30 PM  Q&A Panel & Post-Session Assessment

2:30 – 2:40 PM  Break

SESSION V: WEIGHT LOSS STRATEGIES: FOCUS ON FASTING AND PHARMACOTHERAPY STRATEGIES

2:40 – 2:45 PM  Pre-Session Assessment

2:45 – 3:05 PM  Intermittent Fasting with Focus on Cardiometabolic Risk Factors  
Tracy Severson, RDN, LD

3:05 – 3:25 PM  Update on Pharmacotherapy for Obesity  
Harold E. Bays, MD, FNLA*

3:25 – 3:40 PM  Q&A Panel & Post-Session Assessment

3:40 – 3:50 PM  Break

SESSION VI: THE JOURNAL OF CLINICAL LIPIDOLOGY LIVE ROUNDTABLE

3:50 – 3:55 PM  Overview from Moderator

3:55 – 4:05 PM  What you may have Missed from the Journal of Clinical Lipidology in 2019: High-Level Review of Findings from Three Important Articles  
Catherine G. Derington, PharmD, MS

4:05 – 4:15 PM  Joseph C. DeBoe, DNP, ACNPC-AG

4:15 – 4:25 PM  Lauren A. Williams, MCN, RD, LD

4:25 – 5:00 PM  Experts Panel Roundtable with John R. Guyton, MD, FNLA

5:00 – 5:20 PM  Q&A Panel

5:30 – 7:30 PM  Satellite Symposium

Sunday, March 1

7:00 – 7:50 AM  Breakfast

7:50 – 8:00 AM  Opening Remarks

SESSION VII: LIFESTYLE AND DIET CHALLENGES

8:00 – 8:05 AM  Pre-Session Assessment

8:05 – 8:25 AM  Ultra-Processed vs. Unprocessed Foods  
Tracy Severson, RDN, LD

8:25 – 8:45 AM  Behavioral Treatment Programs to Address Lifestyle and Diet Challenges in Primary Care  
Jun Ma, MD, PhD

8:45 – 9:05 AM  Low-CHO/Very-Low-CHO Diets Scientific Statement  
Carol Kirkpatrick, PhD, RDN, MPH, CLS, FNLA

9:05 – 9:30 AM  Q&A Panel & Post-Session Assessment

9:30 – 9:40 AM  Break

SESSION VIII: IS THE RISING TIDE OF SUPPORT FOR EPA WARRANTED OR JUST ANOTHER FISH-TALE?

9:40 – 9:45 AM  Pre-Session Assessment

9:45 – 10:05 AM  Physiologic and Epidemiologic Evidence for EPA  
Kevin C. Maki, PhD, CLS, FNLA

10:05 – 10:25 AM  AHA Science Advisory on Omega-3 Fatty Acids for the Management of Hypertriglyceridemia  
Ann C. Skulas-Ray, PhD

10:25 – 10:45 AM  Dietary Interventions and Nutritional Supplements: Effects on Cardiovascular Outcomes  
Sarah L. Anderson, PharmD

10:45 – 11:05 AM  Q&A Panel & Post-Session Assessment

11:05 AM  Adjourn

*Diplomate, American Board of Clinical Lipidology
Christie M. Ballantyne, MD, FNLA**
Professor of Medicine
Vice Chair of Research for the Department of Medicine
Chief, Section of Cardiovascular Research
Chief, Section of Cardiology
Department of Medicine
Baylor College of Medicine
Houston, TX

Casey Elkins, DNP, MEd, NP-C, CLS, FNLA
Treasurer, Southeast Lipid Association
Assistant Dean for Academic Affairs
Director, DNP Program
University of South Alabama
College of Nursing
Mobile, AL

Anne C. Goldberg, MD, FNLA*
President, Foundation of the NLA
Professor of Medicine
Washington University School of Medicine
St. Louis, MO

Peter H. Jones, MD, FNLA**
Chief Science Officer, National Lipid Association
Associate Professor
Baylor College of Medicine
Houston, TX

Carol Kirkpatrick, PhD, RDN, MPH, CLS, FNLA*
Director/Clinical Associate Professor
Wellness Center
Idaho State University
Kasiska Division of Health Sciences
Pocatello, ID

Joseph L. Lillo, DO, FNLA
President, Southwest Lipid Association
Assistant Professor of Family Medicine
Midwestern University College of Osteopathic Medicine
Glendale, AZ
Clinical Lipidologist
Lillo Family Medicine
Scottsdale, AZ
Principal Investigator
Elite Clinical Studies
Phoenix, AZ

Pamela B. Morris, MD, FNLA*
Secretary/Treasurer, National Lipid Association
Director, Preventive Cardiology
Co-Director, Women's Heart Care
Medical University of South Carolina
Mt. Pleasant, SC

Alan T. Remaley, MD, PhD
Section Chief Lipoprotein Metabolism Laboratory
National Heart, Lung, and Blood Institute
National Institutes of Health
Bethesda, MD

Joseph J. Saseen, PharmD, CLS, FNLA*
President-Elect, National Lipid Association
Professor and Vice Chair
Skaggs School of Pharmacy and Pharmaceutical Sciences
University of Colorado
Anschutz Medical Campus
Aurora, CO

Daniel E. Soffer, MD, FNLA*
University of Pennsylvania Health System
Internal Medicine/Clinical Lipidology
Perelman Center for Advanced Medicine
Philadelphia, PA

Eric K. Gupta, PharmD, CLS, FNLA*
President, Pacific Lipid Association
Assistant Dean, External Relations and Strategy Initiatives
Associate Professor
Pharmacy Practice and Administration
Western University of Health Sciences
College of Pharmacy
Pomona, CA

*Denotes Diplomate, American Board of Clinical Lipidology
+Denotes Program Faculty
Faculty Subject to Change
PROGRAM FACULTY

Zahid Ahmad, MD
Associate Professor of Internal Medicine
Co-Director, Familial Hypercholesterolemia Clinic
UT Southwestern Medical Center
Dallas, TX

Sarah L. Anderson, PharmD
Associate Professor
Skaggs School of Pharmacy and Pharmaceutical Sciences
University of Colorado
Clinical Pharmacy Specialist
Denver Health Medical Center
Aurora, CO

Harold E. Bays, MD, FNLA*
Medical Director/President
Louisville Metabolic and Atherosclerosis Research Center
Louisville, KY

Kim K. Birtcher, PharmD, CLS, FNLA
Clinical Professor
University of Houston College of Pharmacy
Houston, TX

Alan S. Brown, MD, FNLA*
Director, Division of Cardiology
Advocate Heart Institute
Advocate Lutheran General Hospital
Co-Director, Cardiology Service Line
Advocate Medical Group
Chicago, IL

Mary Katherine Cheeley, PharmD, CLS, FNLA
Clinical Pharmacist Specialist
Grady Health System
Atlanta, GA

Joseph C. DeBoe, DNP, ACNPC-AG
Clinical Assistant Professor
University of Arizona
College of Nursing
Tucson, AZ

Catherine G. Derington, PharmD, MS
Pharmacist
Aurora, CO

P. Barton Duell, MD, FNLA
Professor of Medicine
Director, Lipid-Atherosclerosis Laboratory
Director, Sterol Analysis Laboratory
Director, LDL Apheresis Unit
Center for Preventive Cardiology
Div. Endocrinology, Diabetes and Clinical Nutrition
Oregon Health and Science University
Portland, OR

John R. Guyton, MD, FNLA*
Professor of Medicine
Assistant Professor of Pathology
Department of Medicine
Duke University School of Medicine
Durham, NC

Donald G. Lamprecht, Jr., PharmD, BCPS, CLS, FNLA
Clinical Pharmacy Specialist
Kaiser Permanente Colorado
Clinical Assistant Professor
Skaggs School of Pharmacy and Pharmaceutical Sciences
University of Colorado
Anschutz Medical Campus
Aurora, CO

Rachel Lowe, PharmD, BCPS
Assistant Professor
Skaggs School of Pharmacy and Pharmaceutical Sciences
University of Colorado
Anschutz Medical Campus
Aurora, CO

Jun Ma, MD, PhD
Beth and George Vitoux Professor
Director, Research and Education in Aging
Department of Medicine
University of Illinois at Chicago
Chicago, IL

Kevin C. Maki, PhD, CLS, FNLA
Executive Council Chair, National Lipid Association
Midwest Biomedical Research
Chicago, IL
Indiana University School of Public Health
Bloomington, IN

Margo B. Minissian, PhD, ACNP, CLS, FNLA
Research Scientist
Nurse Practitioner, Cardiology
Director, Postpartum Heart Health Program
Los Angeles, CA

Tracy Severson, RDN, LD
Dietician, Center for Preventive Cardiology
Oregon Health & Science University
Portland, OR

Lauren Williams, MCN, RD, LD
Clinical Dietitian II
Division of Pediatric Endocrinology
Cook Children’s Medical Center
Fort Worth, TX

Mary Katherine Cheeley, PharmD, CLS, FNLA
Clinical Pharmacist Specialist
Grady Health System
Atlanta, GA

Catherine G. Derington, PharmD, MS
Pharmacist
Aurora, CO

P. Barton Duell, MD, FNLA
Professor of Medicine
Director, Lipid-Atherosclerosis Laboratory
Director, Sterol Analysis Laboratory
Director, LDL Apheresis Unit
Center for Preventive Cardiology
Div. Endocrinology, Diabetes and Clinical Nutrition
Oregon Health and Science University
Portland, OR

John R. Guyton, MD, FNLA*
Professor of Medicine
Assistant Professor of Pathology
Department of Medicine
Duke University School of Medicine
Durham, NC

Donald G. Lamprecht, Jr., PharmD, BCPS, CLS, FNLA
Clinical Pharmacy Specialist
Kaiser Permanente Colorado
Clinical Assistant Professor
Skaggs School of Pharmacy and Pharmaceutical Sciences
University of Colorado
Anschutz Medical Campus
Aurora, CO

Rachel Lowe, PharmD, BCPS
Assistant Professor
Skaggs School of Pharmacy and Pharmaceutical Sciences
University of Colorado
Anschutz Medical Campus
Aurora, CO

Jun Ma, MD, PhD
Beth and George Vitoux Professor
Director, Research and Education in Aging
Department of Medicine
University of Illinois at Chicago
Chicago, IL

Kevin C. Maki, PhD, CLS, FNLA
Executive Council Chair, National Lipid Association
Midwest Biomedical Research
Chicago, IL
Indiana University School of Public Health
Bloomington, IN

Margo B. Minissian, PhD, ACNP, CLS, FNLA
Research Scientist
Nurse Practitioner, Cardiology
Director, Postpartum Heart Health Program
Los Angeles, CA

Tracy Severson, RDN, LD
Dietician, Center for Preventive Cardiology
Oregon Health & Science University
Portland, OR

Lauren Williams, MCN, RD, LD
Clinical Dietitian II
Division of Pediatric Endocrinology
Cook Children’s Medical Center
Fort Worth, TX

*Denotes Diplomate, American Board of Clinical Lipidology
Welcome Reception
Friday, February 28 | 6:00 – 7:00 PM
Join your colleagues and our exhibitors for an opening reception on Friday evening in the exhibit hall. Visit with exhibiting companies and mingle, while enjoying tasty hors d’oeuvres and cocktails. This reception is included in the registration; guests with a guest pass are also welcome.

New Member Game Night
Saturday, February 29 | 7:30 – 9:00 PM
If you are new to the NLA, you must attend this event - sure to be filled with fun, food, drinks and a time you won’t forget. This is your chance to meet and build relationships with national and chapter leaders in a relaxed atmosphere. The night will feature a Family Feud-style round of games to get everyone engaged and having some fun - you might even walk away with a prize.

Expert Theater Presentations
Saturday, February 29 | 12:00 – 1:00 PM
Enjoy lunch on Saturday while seeing one of two intriguing lectures from our industry supporters. Stay tuned to your inbox for more details!

Women in Lipidology Event
Saturday, February 29 | 7:00 – 7:30 PM
Stay tuned for more information regarding the Women in Lipidology networking event that will be held in Denver. This group is geared for any woman with an interest in lipidology and is open for all to attend. Make sure to follow us on @NLAWIL on Twitter for more information regarding the upcoming event at the 2020 Spring Clinical Lipid Update.
VENUE INFORMATION

Grand Hyatt Denver
1750 Welton Street, Denver, Colorado, United States, 80202
DENVER.GRAND.HYATT.COM/DENVER

Denver, the capital of Colorado, was founded in 1858 at the foothills of the Rocky Mountains as a gold mining town. Its long history is reflected in many of the city’s 19th-century buildings and historical landmarks.

Although Denver’s nickname is the “Mile-High City” (its official elevation is one mile above sea level, defined by a benchmark on the steps of the State Capitol building), the elevation of the entire city ranges from 5,130 to 5,690 feet (1,560 to 1,730 meters). Because of the high altitude, visitors are encouraged to hydrate often due to the loss of water through respiration at twice the rate as at sea level.

What to Do in Denver?

EXPLORE
If you’re looking for a taste of crisp mountain air in the great outdoors while visiting, there are hundreds of scenic settings in and around Denver ideal for a visit. For those who prefer to stay closer to town, the 177-acre Sloan’s Lake park is one of the best locations for watching a sunset, offering stunning views of both the snow-covered Rocky Mountains and the Denver skyline.

SHOP
From souvenirs for your loved ones to unique collector items, the one-square-mile South Broadway shopping district’s vibrant collection of vintage and antique shops, bookstores, galleries, local craft shops and more guarantee you’ll find what you’re looking for...or maybe even find something you never knew you had to have! The thoroughfare is just a short taxi ride south of the NLA Spring CLU host hotel.

CHEERS
For true connoisseurs of bubbly brews, Denver is a prime bucket list destination. The strength of the local beer culture is evidenced by the 100 local brewpubs, breweries and tap rooms in the metro area. Locals recommend that those who are interested in getting a taste of the local flavors (safely and responsibly, of course) use the #DenverBeerTrail as your guide.

To explore more fun things to do in Denver, go to denver.org.

NLA Room Rate
$199 per night plus tax

The cutoff date to receive the NLA group discount is February 5, 2020 or until the block is full.

Centrally located in the heart of downtown Denver and proximate to the area’s entertainment, business, and theater districts, the elegant, AAA Four-diamond Grand Hyatt Denver offers an atmosphere of refined elegance.

The hotel’s room accommodations – among the region’s largest – feature the popular Hyatt Grand bed, well-lit work stations and free guest room WiFi. If your schedule permits, the hotel offers several exercise options including an indoor pool, complimentary 24-hour fitness center and an outdoor jogging track.

For reservations, visit the Venue tab on lipid.org/springclu or call 866-238-4218.
**PROGRAM OVERVIEW**

**Target Audience**
This activity is designed to meet the needs of physicians, physician assistants, pharmacists, registered nurses, nurse practitioners, advance practice registered nurses, and registered dietitians with an interest in lipid management.

**Type of Activity**
Live Activity
Application

---

**Educational Objectives**
At the conclusion of this activity, all participants should be able to:
- Discuss strategies to improve the knowledge, skills or performance of the healthcare team.

**Session I: Drugs in the Pipeline**
- Discuss the role of novel therapies for the future clinical management of patients with dyslipidemia.

**Session II: Fortune-Tellers and Crystal Balls in ASCVD: Divining and Refining Risk Assessment**
- Explain new refinements in the assessment of ASCVD risk in primary prevention patients.
- Recognize challenges in classifying patient risk for ASCVD.
- Summarize recent advancements in the use of genetics in primary prevention ASCVD risk assessment.

**Session III: One Size Does Not Fit All: Evidence-Based use of Statin Therapy in Special Populations**
- Discuss potential statin drug-drug interactions in special populations.
- Describe the appropriate usage of statins in patients with chronic kidney disease.
- Identify potential benefits and risks of statin use in the elderly.

**Session IV: Improving Outcomes for the Statin Intolerant Patient**
- Summarize the evidence-based recommendations for current and emerging non-statin therapeutic interventions.
- Demonstrate the potential use of non-statin therapies in an overall cardiovascular disease risk reduction management plan in patients not able to tolerate or resistant to statin therapy.

**Session V: Weight Loss Strategies: Focus on Fasting and Pharmacotherapy Strategies**
- Outline the impact of various diets on short-term and long-term weight loss.
- Discuss pharmacologic therapy options for the treatment of obesity.

**Session VI: The Journal of Clinical Lipidology Live Roundtable**
- Review the practical application of recent publications to the clinical evaluation and management of patients with dyslipidemia.

**Session VII: Lifestyle and Diet Challenges**
- Compare and contrast nutrition options in the management of patients with dyslipidemia.
- Demonstrate counseling techniques for modifying diet and lifestyle.
- Outline the impact of various diets on short-term and long-term cardiovascular risks.

**Session VIII: Is the Rising Tide of Support for EPA Warranted or Just Another Fish-Tale?**
- Describe the evidence to support the benefit of omega-3 fatty acids.
- Identify the recent clinical trial evidence for the use of omega-3 fatty acids in dyslipidemia management.
- Discuss evidence that supports the benefits of nutritional supplements and dietary counseling in reducing cardiovascular disease.

---

**Criteria for Success:**
Statements of credit will be awarded based on the participant’s attendance and submission of the activity evaluation form. A statement of credit will be available upon completion of an online evaluation/claimed credit form at lipid.org/cme.

*For Pharmacists:* Upon successful completion of the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

*For Dietitians:* Upon completion of the activity evaluation form, dietitians may submit evaluations of the quality of activities/materials to CDR. Poor evaluations of activities/materials may trigger an audit of the activities/materials by CDR.

**Disclosure Statement:**
It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by NLA prior to accreditation of the activity.

**Commercial Support:**
Full notification of commercial support will be provided in the activity syllabus.
Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.

The maximum number of hours awarded for this CE activity is 15.0 contact hours.

Nursing dietetic technicians, registered (DTRs) will receive 15.00 continuing professional education units (CPEUs) for completion of this program/materials. CDR Accredited Provider #NL002.

The National Lipid Association is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 12.00 continuing professional education units (CPEUs) for completion of this program/materials. CDR Accredited Provider #NL002.

The National Lipid Association designates this live activity for a maximum of 13.25 AMA PRA Category 1 Credit(s)*. Physicians should claim only credit commensurate with the extent of their participation in this activity.

Nursing

The maximum number of hours awarded for this CE activity is 12.0 contact hours.

Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.

The maximum number of hours awarded for this CE activity is 12.0 contact hours.

Nursing

The maximum number of hours awarded for this CE activity is 12.0 contact hours.

Physician Assistants

NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

Dietitians

The National Lipid Association is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 13 continuing professional education units (CPEUs) for completion of this program/materials. CDR Accredited Provider #NL002.

The National Lipid Association designates this live activity for a maximum of 13.25 AMA PRA Category 1 Credit(s)*. Physicians should claim only credit commensurate with the extent of their participation in this activity.

Physician Assistants

NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

Dietitians

The National Lipid Association is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 12.0 continuing professional education units (CPEUs) for completion of this program/materials. CDR Accredited Provider #NL002.

The National Lipid Association designates this live activity for a maximum of 12.00 AMA PRA Category 1 Credit(s)*. Physicians should claim only credit commensurate with the extent of their participation in this activity.

Nursing

The maximum number of hours awarded for this CE activity is 12.0 contact hours.

Physician Assistants

NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

Dietitians

The National Lipid Association is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 12.0 continuing professional education units (CPEUs) for completion of this program/materials. CDR Accredited Provider #NL002.

The National Lipid Association designates this live activity for a maximum of 12.00 AMA PRA Category 1 Credit(s)*. Physicians should claim only credit commensurate with the extent of their participation in this activity.

Nursing

The maximum number of hours awarded for this CE activity is 12.0 contact hours.

Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.

The maximum number of hours awarded for this CE activity is 12.0 contact hours.

Nursing

The maximum number of hours awarded for this CE activity is 12.0 contact hours.

Physician Assistants

NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

Dietitians

The National Lipid Association is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 12.0 continuing professional education units (CPEUs) for completion of this program/materials. CDR Accredited Provider #NL002.

The National Lipid Association designates this live activity for a maximum of 12.00 AMA PRA Category 1 Credit(s)*. Physicians should claim only credit commensurate with the extent of their participation in this activity.

Nursing

The maximum number of hours awarded for this CE activity is 12.0 contact hours.

Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.

The maximum number of hours awarded for this CE activity is 12.0 contact hours.

Nursing

The maximum number of hours awarded for this CE activity is 12.0 contact hours.

Physician Assistants

NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

Dietitians

The National Lipid Association is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 12.0 continuing professional education units (CPEUs) for completion of this program/materials. CDR Accredited Provider #NL002.

The National Lipid Association designates this live activity for a maximum of 12.00 AMA PRA Category 1 Credit(s)*. Physicians should claim only credit commensurate with the extent of their participation in this activity.

Nursing

The maximum number of hours awarded for this CE activity is 12.0 contact hours.

Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.

The maximum number of hours awarded for this CE activity is 12.0 contact hours.

Nursing

The maximum number of hours awarded for this CE activity is 12.0 contact hours.

Physician Assistants

NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

Dietitians

The National Lipid Association is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 12.0 continuing professional education units (CPEUs) for completion of this program/materials. CDR Accredited Provider #NL002.

The National Lipid Association designates this live activity for a maximum of 12.00 AMA PRA Category 1 Credit(s)*. Physicians should claim only credit commensurate with the extent of their participation in this activity.

Nursing

The maximum number of hours awarded for this CE activity is 12.0 contact hours.

Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.

The maximum number of hours awarded for this CE activity is 12.0 contact hours.

Nursing

The maximum number of hours awarded for this CE activity is 12.0 contact hours.

Physician Assistants

NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

Dietitians

The National Lipid Association is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 12.0 continuing professional education units (CPEUs) for completion of this program/materials. CDR Accredited Provider #NL002.

The National Lipid Association designates this live activity for a maximum of 12.00 AMA PRA Category 1 Credit(s)*. Physicians should claim only credit commensurate with the extent of their participation in this activity.

Nursing

The maximum number of hours awarded for this CE activity is 12.0 contact hours.

Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.

The maximum number of hours awarded for this CE activity is 12.0 contact hours.

Nursing

The maximum number of hours awarded for this CE activity is 12.0 contact hours.

Physician Assistants

NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

Dietitians

The National Lipid Association is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 12.0 continuing professional education units (CPEUs) for completion of this program/materials. CDR Accredited Provider #NL002.

The National Lipid Association designates this live activity for a maximum of 12.00 AMA PRA Category 1 Credit(s)*. Physicians should claim only credit commensurate with the extent of their participation in this activity.

Nursing

The maximum number of hours awarded for this CE activity is 12.0 contact hours.

Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.

The maximum number of hours awarded for this CE activity is 12.0 contact hours.

Nursing

The maximum number of hours awarded for this CE activity is 12.0 contact hours.

Physician Assistants

NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

Dietitians

The National Lipid Association is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 12.0 continuing professional education units (CPEUs) for completion of this program/materials. CDR Accredited Provider #NL002.

The National Lipid Association designates this live activity for a maximum of 12.00 AMA PRA Category 1 Credit(s)*. Physicians should claim only credit commensurate with the extent of their participation in this activity.

Nursing

The maximum number of hours awarded for this CE activity is 12.0 contact hours.

Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.

The maximum number of hours awarded for this CE activity is 12.0 contact hours.

Nursing

The maximum number of hours awarded for this CE activity is 12.0 contact hours.

Physician Assistants

NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

Dietitians

The National Lipid Association is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 12.0 continuing professional education units (CPEUs) for completion of this program/materials. CDR Accredited Provider #NL002.

The National Lipid Association designates this live activity for a maximum of 12.00 AMA PRA Category 1 Credit(s)*. Physicians should claim only credit commensurate with the extent of their participation in this activity.

Nursing

The maximum number of hours awarded for this CE activity is 12.0 contact hours.

Pharmacotherapy contact hours for Advance Practice Registered Nurses to be determined.
Foundations of Lipidology

Pre-conference Course
Thursday, February 27 | 8:00 AM – 5:35 PM
Friday, February 28 | 8:00 AM – 2:30 PM

Course Faculty

Carol Kirkpatrick, PhD, MPH, RDN, CLS, FNLA
Director/ Clinical Associate Professor
Wellness Center
Idaho State University
Kasiska Division of Health Sciences
Pocatello, ID

Ann Liebeskind, MD, FNLA*
Founder, Complex Lipids Clinic
Mobile Health Team
Neenah & Wauwatosa, WI

Joseph J. Saseen, PharmD, CLS, FNLA
Course Co-Chair
President-Elect, National Lipid Association
Professor and Vice Chair
Skaggs School of Pharmacy and Pharmaceutical Sciences
University of Colorado
Anschutz Medical Campus
Aurora, CO

Daniel E. Soffer, MD, FNLA*
Course Co-Chair
University of Pennsylvania Health System
Internal Medicine/Clinical Lipidology
Perelman Center for Advanced Medicine
Philadelphia, PA

*Denotes Diplomate, American Board of Clinical Lipidology (ABCL)
Faculty subject to change

For more information please visit: lipid.org/foundations
Masters in LIPIDOLOGY

Pre-conference Course
Thursday, February 27 | 7:30 AM – 5:40 PM
Friday, February 28 | 7:30 AM – 2:20 PM

Course Faculty

$750 NLA Members
$1,250 Non-Members
$395 Trainees

Overview
The NLA’s Masters in Lipidology course provides an advanced examination of the core curriculum in Clinical Lipidology. This course is designed for any health care professional with experience in Lipidology who desires advanced training. Experts in the field of Lipidology will lecture on advanced concepts and guide participants through interactive learning scenarios that provide tools and skills to further advance personal standards of practice. It is recommended that attendees have already completed preparatory coursework (e.g., Foundations of Lipidology or similar core curriculum training).

This course is particularly useful to explore the details of Clinical Lipidology and is appropriate for clinicians from the full spectrum of clinical experience including physicians, physician assistants, nurse practitioners, pharmacists, exercise physiologists, and dietitians who are in any phase of training, or even experienced physicians who are looking to take a deeper dive into Lipidology.

Masters in Lipidology is offered as a two-day course prior to NLA meetings (Clinical Lipid Updates [CLU] and Scientific Sessions).

Target Audience
This activity is designed to meet the needs of physicians, physician assistants, pharmacists, registered nurses, advanced practice registered nurses, nurse practitioners and registered dietitians with expertise in Lipidology looking for further advanced training.

Type of Activity
Application

For more information please visit: lipid.org/masters

*Denotes Diplomate, American Board of Clinical Lipidology (ABCL)
Faculty subject to change